Unity Biotechnology, Inc. Overview
Pro stress-test →Unity Biotechnology was a biotechnology company that developed therapeutics to slow, halt, or reverse diseases of aging, with a focus on senolytic medicines that clear senescent cells from the human body. The company operated until 2025 and had a pipeline targeting ophthalmology, pulmonary, and age-related diseases.
Strategic Profile
Pro stress-test →The company pioneered the senolytic drug class, positioning itself in the emerging longevity/aging-biology space with backing from notable investors including Jeff Bezos and Peter Thiel. Its lead candidate UBX1325 advanced through Phase 2 clinical trials for age-related eye diseases, demonstrating vision gains comparable to standard treatments.
Competitive Landscape
Pro stress-test →Competitors in the aging/senolytic space included traditional ophthalmology players like Regeneron (aflibercept), AbbVie in age-related disease spaces, and emerging longevity biotech companies. Unity's differentiation was its senolytic mechanism targeting senescent cell clearance, but the company could not sustain commercial viability.
Industry Context
Unity Biotechnology, Inc. operates in Biotechnology - Senolytic Therapeutics / Aging/Longevity.
Key facts
Founded: 2009 · Headquarters: South San Francisco, California